Stem Cell Clinics Promise Miracle Cures, but at What Cost to Patients?
By Philip Perry,
Big Think
| 11. 13. 2016
Stem cell clinics have popped up all over the country, promising vast improvements in serious conditions, and offering patient testimonials to back up their claims. At the same time, these clinics are skating a line, carefully warning that these are anecdotal statements and that such treatment “…is not a cure for any medical condition.” This particular legal statement comes from the website of StemGenex, of La Jolla, Calif., recently the focus of an exposé by the L.A. Times.
Such clinics use direct marketing techniques to approach patients with serious conditions, hinting that an “intervention” will improve symptoms dramatically. Alzheimer’s patients and those who have children with autism are particularly targeted. According to one researcher, who attended an informational session at a clinic, “There were people in the audience suffering from various conditions that made them a fairly vulnerable population.” Some experts wonder whether the dramatic turnarounds patients claim in testimonials is not just the placebo effect or a short-term improvement, which may not last.
Over 500 stem cell clinics have opened their doors across the country...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...